Flecainide- NTID [Design Issues]

posted by dr.who – Macedonia, 2018-06-28 01:32 (2566 d 07:57 ago) – Posting: # 18985
Views: 4,146

Thanks for the feedback.

Yes,you are right. All availabe PARS show BE with standard acceptance limits.

But, the originator SmPC states that flecainide is NTID:
"Flecainide as a narrow therapeutic index drug requires caution and close monitoring when switching a patient to a different formulation."

https://www.medicines.org.uk/emc/product/829/smpc

Also, I found this study which consider the NTI for flecainide and regulatory requirements per region.\
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412688/

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,681 registered users;
65 visitors (0 registered, 65 guests [including 14 identified bots]).
Forum time: 09:30 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5